

XVIVO Perfusion – Consensus estimates Q3 2024

Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.

Number of contributors: 5 (all of which have been updated or confirmed before the report)

KPI (MSEK, unless otherwise specified)	Q3 2024E
Net sales	208
Organic growth in local currency (%)	37.2
Gross profit	155
EBITDA	41
EBIT	23
Net profit	21
Earnings per share (SEK)	0.69
Net sales per segment:	
Thoracic	136
Abdominal	47
Services	24

XVIVO Perfusion's Q3 report will be released on Thursday, 24 October, at 07:30 CEST.